Siklos (hydroxyurea)

Indicaton

Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome

Therapeutic indications

Genetic disorder

Type of product

Small molecule

Table

Phase

Filing
Partnering status

Partnered
Partner

Addmedica
Available in

Switzerland

You may also be interested in

nizubaglustat

Has the potential to treat multiple rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses, and Niemann-Pick disease type C (NPC).

Phase II started

Bimiralisib, topical [PQR309] (panPI3K/mTOR)

Non-melanoma skin cancers and rare genetic skin manifestations.

Discovery

TA-46

Achondroplasia